https://ir.stockpr.com/cytodyn/sec-filings-email/c

https://ir.stockpr.com/cytodyn/sec-filings-em...def14a.htm

October 11, 2024

Dear CytoDyn Stockholder:

You are cordially invited to virtually attend the 2024 Annual Meeting of Stockholders of CytoDyn Inc. (the “Company”) to be held solely online via a live webcast at 9:30 am, Pacific Time, on November 22, 2024, at https://meetnow.global/MZM9KKF. There is no physical location for the Annual Meeting. To attend and vote at the Annual Meeting, you must be a stockholder of record as of the close of business on September 30, 2024, or hold a legal proxy, as explained in the “Voting, Revocation, and Solicitation of Proxies” and “Attendance at the Annual Meeting” sections of the accompanying proxy statement.

The matters to be presented for action at the Annual Meeting are (i) the election of five directors to our Board of Directors; (ii) ratification, on an advisory (non-binding) basis, of the appointment of our auditors, Marcum LLP; and (iii) approval, on an advisory (non-binding) basis, of our named executive officer compensation. We may also act on such other business as may properly come before the Annual Meeting.

We are excited about the future of our company. It is vitally important that your shares are represented and voted, whether or not you are able to attend the virtual meeting. We urge you to promptly vote and submit your proxy (1) via the Internet, (2) by phone, or (3) if you received your proxy materials by mail, by signing, dating, and returning the enclosed proxy card or voting instruction form in the envelope provided for your convenience.

Sincerely,
Dr. Jacob Lalezari
Chief Executive Officer

The Annual Meeting is being held to consider and vote on the following matters:

1. Election of five (5) directors to serve on the Board of Directors until the 2025 Annual Meeting of Stockholders, until their successors are duly elected and qualified or until their earlier death, resignation or removal;
2. Ratification, on an advisory (non-binding) basis, of the selection of Marcum LLP as our independent registered public accounting firm for the fiscal year ending May 31, 2025;
3. Approval, on an advisory (non-binding) basis, of our named executive officer compensation; and
4. Transaction of any other business as may properly come before the Annual Meeting or any postponements or adjournments thereof.

My comments are just my opinions and should NOT be taken as investment advice.